List view / Grid view
22 September 2015 | By Victoria White
Both Phase 3 studies met their primary endpoints as measured by the proportion of patients receiving tofacitinib in remission at Week 8 compared to patients receiving placebo...
9 September 2015 | By Victoria White
The trial will evaluate the safety of Eliquis versus warfarin or other vitamin K antagonists in patients with nonvalvular atrial fibrillation and a recent acute coronary syndrome or undergoing percutaneous coronary intervention...
26 August 2015 | By Victoria White
Alvogen is to acquire four pharmaceutical products from Pfizer, strengthening Alvogen’s commercial platform in the US market...
26 August 2015 | By Victoria White
Alliance Foundation Trials, the Austrian Breast & Colorectal Cancer Study Group and Pfizer have launched the Palbociclib Collaborative Adjuvant Study...
21 August 2015 | By Victoria White
Pfizer has announced positive topline results of two Phase 3 studies of Trumenba (Meningococcal Group B Vaccine). Both studies met all primary endpoints...
21 August 2015 | By Victoria White
The EMA has validated for review a MAA for Ibrance in combination with endocrine therapy for the treatment of HR+/HER2- metastatic breast cancer...
6 August 2015 | By Victoria White
The CMA has accused Pfizer and Flynn Pharma of charging excessive and unfair prices in the UK for phenytoin sodium capsules, an anti-epilepsy drug...
5 August 2015 | By Victoria White
The ECs has approved Pfizer’s pending acquisition of Hospira - a transaction that will greatly expand Pfizer's sterile injectable pharmaceuticals portfolio...
4 August 2015 | By Victoria White
Pfizer and Synthon have entered into an agreement whereby Pfizer has acquired the exclusive commercialisation rights in the US to glatiramer acetate...
7 July 2015 | By Victoria White
A new study has found that less than 1% of 11,000 healthy volunteers who participated in 394 Phase I trials for new drugs experienced serious complications...
7 July 2015 | By Victoria White
The first patients have been enrolled in a Phase 2b clinical trial of Pfizer’s S. aureus vaccine in adults undergoing elective spinal fusion surgery...
3 July 2015 | By Victoria White
The FDA has accepted for review Pfizer’s new drug application (NDA) for Xeljanz (tofacitinib citrate) 11 mg once daily modified release tablets...
24 June 2015 | By Victoria White
The first patient has been enrolled in Pfizer’s RESET study of rivipansel for the treatment of vaso-occlusive crisis in patients with sickle cell disease...
22 June 2015 | By Victoria White
Full results from the second part of a Phase 3 trial evaluating the safety and efficacy of andexanet alfa as a reversal agent of Eliquis have been announced...
22 June 2015 | By Victoria White
Pfizer has entered into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for $130 million...
